Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01862224 · ClinicalTrials.gov registry record · Phase 2
A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
A Phase 2 study, sponsored by Janssen Research & Development.
- Terminated
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT01862224 is a Phase 2 study that was terminated before completion, run by Janssen Research & Development. The registered enrollment target is 21 participants.
The verdict
NCT01862224, a Phase 2 study, was terminated before completion, sponsored by Janssen Research & Development.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the impact of JNJ-38518168 on rheumatoid arthritis (RA) disease-related biomarkers in synovial biopsy tissue and blood in participants with active RA despite methotrexate (MTX) therapy and to assess the safety and tolerability of JNJ-38518168 over one year.
Interventions
- DRUG Placebo
- DRUG Methotrexate
- DRUG JNJ-38518168
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2013-07 |
| Est. Completion | 2014-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01862224
The ClinicalTrials.gov registry entry for NCT01862224 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01862224 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01862224 about?
NCT01862224 is a clinical study titled "A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy". The purpose of this study is to assess the impact of JNJ-38518168 on rheumatoid arthritis (RA) disease-related biomarkers in synovial biopsy tissue and blood in participants with active RA despite methotrexate (MTX) therapy and to assess the safety and tolerability of JNJ-38518168 over one year.
What is the current status of trial NCT01862224?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2013-07. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01862224?
The interventions under investigation include: Placebo (DRUG), Methotrexate (DRUG), JNJ-38518168 (DRUG).
Who is sponsoring clinical trial NCT01862224?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.